Annual Report 2022

FINANCIAL HIGHLIGHTS 5 The United Laboratories International Holdings Limited Annual Report 2022 0 2,000 4,000 6,000 8,000 10,000 12,000 0 500 1,000 1,500 2,000 2,500 3,000 0 20 40 60 80 100 0 500 1,000 1,500 2,000 1,700.3 3,968.6 4,034.5 1,233.6 3,389.7 2,887.3 7,510.6 8,392.6 1,280.4 3,593.1 3,519.1 8,772.5 1,429.7 3,620.7 3,722.1 9,703.4 1,599.2 5,174.7 4,560.4 11,334.3 41.8 39.1 39.8 53.7 86.89 641.8 682.9 703.0 988.1 1,581.1 1,833.7 2,640.8 1,788.4 1,798.2 1,678.1 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 Intermediate products Bulk medicine Finished products BASIC EARNINGS PER SHARE (RMB million) PROFIT FOR THE YEAR ATTRIBUTABLE TO OWNERS OF THE COMPANY (RMB million) 2022 2021 Increase RMB’000 RMB’000 % Revenue 11,334,262 9,703,438 16.8% EBITDA 2,640,792 1,883,735 40.2% Profit before taxation 2,006,766 1,202,647 66.9% Profit for the year attributable to owners of the Company 1,581,094 988,098 60.0% RMB cents RMB cents Earnings per share - Basic 86.89 53.70 61.8% Dividend per share – Interim dividend 5.0 4.0 25.0% – Final dividend 14.0 8.0 75.0% – Special dividend 6.0 2.0 200.0% – Full-year dividend 25.0 14.0 78.6% REVENUE (RMB million) EBITDA (RMB million)